IDH1 and neoplasm: Preclinical studies have evidenced that inhibiting IDH1 may stimulate anticancer immunity through the conversion of an immunologically “cold” milieu to “hot”, as well as by determining the restoration of tumor cells’ sensitivity to immunological signals (Figure 2).